LANCASTER, Calif.--(BUSINESS WIRE)--Cognigen Corporation, a wholly owned subsidiary of Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that it has released Version 1.3 of KIWI™, a private, cloud-based platform to efficiently and consistently organize, process, evaluate, and communicate modeling and simulation results.
Mr. Andrew Rokitka, director of Information Technology at Cognigen, said, “The pharmaceutical industry has been rapidly adopting cloud technology as a solution to ever-expanding computer processing needs. Leveraging our 20-plus years of experience in providing an architecture supporting modeling and simulation efforts, we have developed KIWI as a secure, validated, enterprise-scale environment, enabling global teams to collaborate on model-based decision making.”
Ted Grasela, president of Cognigen and Simulations Plus, added, “KIWI has proven to be a valuable platform for encouraging interdisciplinary discussions about the model development process and interpretation of results. We continue to receive positive feedback about the functionality implemented in KIWI and the value of the approach we have taken to harness cloud technology. As Cognigen intends to continue to improve functionality and collaboration within the KIWI platform, the licensing fee will be a source of recurring revenue for further development and growth.”
Dr. Sebastien Bihorel, associate director, Pharmacometrics, added, “This version of KIWI provides our user community with access to new features that accelerate completion of modeling projects by decreasing run times and facilitating the comparison and exporting of results across models. These features include dynamic comparisons of model parameter estimates and diagnostic plots, export of model run records for regulatory submissions, and accelerated infrastructure with the upgrade to the latest versions of NONMEM® and Perl-speaks-NONMEM running in a 64-bit Linux environment.”
About Cognigen Corporation
Cognigen Corporation was founded in 1993 in Buffalo, New York and has grown to become one of the leading providers of population pharmacokinetic and pharmacodynamic modeling and simulation services. The services of the company are well-recognized as providing insightful analysis and reports that guide regulatory decision making, which minimizes follow-up questions from regulators, saving sponsors considerable time and money in getting new pharmaceutical products to market. Cognigen Corporation deployed KIWI in 2011 to provide pharmacometricians and clinical team leads access to a dynamic modeling and simulation platform for population analyses. More information is available on the company’s Web site at www.cognigencorp.com.
About Simulations Plus, Inc.
Simulations Plus, Inc. is a premier developer of groundbreaking drug discovery and development simulation and modeling software that is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. Simulations Plus also recently acquired Cognigen Corporation of Buffalo, New York, adding top-quality statistical modeling and simulation using clinical trial data to its offerings, as well as more than doubling their staff from 30 to over 60, adding nearly 50% to revenues, and increasing earnings in the fiscal year that began September 1, 2014. The Company is headquartered in Southern California and trades on the NASDAQ Capital Market under the symbol “SLP.” Cognigen Corporation remains located in Buffalo, NY. For more information, visit our web site at www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect,” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.
NONMEM® is a registered trademark of ICON plc.
Perl-speaks-NONMEM is a copyrighted set of perl modules developed and maintained by Kajsa Harling and Rikard Nordgren.
